Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis of Multiple Sclerosis

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Haider, Lukas ^a  

^a Medical University of Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIA; NEUROPHYSIOLOGY; OXIDATIVE STRESS; PATHOLOGY;

CENTRAL NERVOUS SYSTEMS; CHRONIC INFLAMMATORY; CLINICAL ASPECTS; DEMYELINATING DISEASE; FREE RADICAL PRODUCTIONS; MULTIPLE SCLEROSIS; NEURODEGENERATION; OXYGEN CONSUMPTION;

FREE RADICALS;

IRON;

APOPTOSIS; AUTOPHAGOSOME; BLOOD BRAIN BARRIER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY CONSUMPTION; HUMAN; HYPOXIA; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; META ANALYSIS (TOPIC); MITOCHONDRIAL RESPIRATION; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; REVIEW; TISSUE INJURY; BRAIN; ENERGY METABOLISM; METABOLISM; MITOCHONDRION; MYELIN SHEATH; PATHOLOGY;

BRAIN; ENERGY METABOLISM; HUMANS; INFLAMMATION; IRON; MITOCHONDRIA; MULTIPLE SCLEROSIS; MYELIN SHEATH; OXIDATIVE STRESS;

EID: 84935908121     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/725370     Document Type: Review

References (152)

1. D. H. Mahad, B. D. Trapp, and H. Lassmann, "Pathological mechanisms in progressive multiple sclerosis, " The Lancet Neurology, vol. 14, no. 2, pp. 183-193, 2015.
2. A. Scalfari, A. Neuhaus, M. Daumer, P. A. Muraro, and G. C. Ebers, "Onset of secondary progressive phase and longterm evolution of multiple sclerosis, " Journal of Neurology, Neurosurgery and Psychiatry, vol. 85, no. 1, pp. 67-75, 2014.
3. A. Compston and A. Coles, "Multiple sclerosis, " The Lancet, vol. 372, no. 9648, pp. 1502-1517, 2008.
4. C. Confavreux, S. Vukusic, T. Moreau, and P. Adeleine, "Relapses and progression of disability in multiple sclerosis, " The New England Journal ofMedicine, vol. 343, no. 20, pp. 1430-1438, 2000.
5. J. M. Frischer, S. Bramow, A. Dal-Bianco, et al., "The relation between inflammation and neurodegeneration inmultiple sclerosis brains, " Brain, vol. 132, no. 5, pp. 1175-1189, 2009.
6. R. Magliozzi, O. W. Howell, C. Reeves, et al., "A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis, " Annals of Neurology, vol. 68, no. 4, pp. 477-493, 2010.
7. B. D. Trapp and K.-A. Nave, "Multiple sclerosis: an immune or neurodegenerative disorder?" Annual Review of Neuroscience, vol. 31, pp. 247-269, 2008.
8. S. Hochmeister, R. Grundtner, J. Bauer, et al., "Dysferlin is a newmarker for leaky brain blood vessels in multiple sclerosis, " Journal of Neuropathology & Experimental Neurology, vol. 65, no. 9, pp. 855-865, 2006.
9. O. Ciccarelli, F. Barkhof, B. Bodini, et al., "Pathogenesis of multiple sclerosis: insights frommolecular and metabolic imaging, " The Lancet Neurology, vol. 13, no. 8, pp. 807-822, 2014.
10. A. E. Cardona, E. P. Pioro, M. E. Sasse, et al., "Control of microglial neurotoxicity by the fractalkine receptor, " Nature Neuroscience, vol. 9, no. 7, pp. 917-924, 2006.
11. S. G. Meuth, O. J. Simon, A. Grimm, et al., "CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing, " Journal of Neuroimmunology, vol. 194, no. 1-2, pp. 62-69, 2008.
12. J. Kolasinski, C. J. Stagg, S. A. Chance, et al., "A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology, " Brain, vol. 135, no. 10, pp. 2938-2951, 2012.
13. V. H. Perry and C. Holmes, "Microglial priming in neurodegenerative disease, " Nature Reviews Neurology, vol. 10, no. 4, pp. 217-224, 2014.
14. A. Kroner, N. Schwab, C. W. Ip, et al., "Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous systemmyelin mutants, " The American Journal of Pathology, vol. 174, no. 6, pp. 2290-2299, 2009.
15. J. J. G. Geurts, E.-J. Kooi, M. E. Witte, and P. van der Valk, "Multiple sclerosis as an inside-out disease, " Annals of Neurology, vol. 68, no. 5, pp. 767-768, 2010.
16. P. K. Stys, G. W. Zamponi, J. van Minnen, and J. J. G. Geurts, "Will the real multiple sclerosis please stand up?" Nature Reviews Neuroscience, vol. 13, no. 7, pp. 507-514, 2012.
17. M. H. Barnett and J. W. Prineas, "Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion, " Annals of Neurology, vol. 55, no. 4, pp. 458-468, 2004.
18. K. J. Smith and H. Lassmann, "The role of nitric oxide in multiple sclerosis, " The Lancet Neurology, vol. 1, no. 4, pp. 232-241, 2002.
19. M. W. Koch, G. S. M. Ramsaransing, A. V. Arutjunyan, et al., "Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis, " Journal of Neurology, vol. 253, no. 4, pp. 483-487, 2006.
20. O. Vladimirova, J. OConnor, A. Cahill, H. Alder, C. Butunoi, and B. Kalman, "Oxidative damage to DNA in plaques of MS brains, " Multiple Sclerosis, vol. 4, no. 5, pp. 413-418, 1998.
21. K. P. Hammann and H. C. Hopf, "Monocytes constitute the only peripheral blood cell population showing an increased burst activity in multiple sclerosis patients, " International Archives of Allergy and Applied Immunology, vol. 81, no. 3, pp. 230-234, 1986.
22. A. Greco, L. Minghetti, G. Sette, C. Fieschi, and G. Levi, "Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis, " Neurology, vol. 53, no. 8, pp. 1876-1879, 1999.
23. I. Nikic, D. Merkler, C. Sorbara, et al., "A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis, " Nature Medicine, vol. 17, no. 4, pp. 495-499, 2011.
24. J. van Horssen, M. E. Witte, G. Schreibelt, and H. E. de Vries, "Radical changes inmultiple sclerosis pathogenesis, " Biochimicaet Biophysica Acta, vol. 1812, no. 2, pp. 141-150, 2011.
25. J. van Horssen, G. Schreibelt, J. Drexhage, et al., "Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression, " Free Radical Biology &Medicine, vol. 45, no. 12, pp. 1729-1737, 2008.
26. L. Haider, M. T. Fischer, J. M. Frischer, et al., "Oxidative damage inmultiple sclerosis lesions, " Brain, vol. 134, no. 7, pp. 1914-1924, 2011.
27. M. Filippi, M. A. Rocca, F. Barkhof, et al., "Association between pathological and MRI findings inmultiple sclerosis, " The Lancet Neurology, vol. 11, no. 4, pp. 349-360, 2012.
28. D. H. Miller, P. Rudge, G. Johnson, et al., "Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis, " Brain, vol. 111, no. 4, pp. 927-939, 1988.
29. M. I. Gaitan, C. D. Shea, I. E. Evangelou, et al., "Evolution of the blood-brain barrier in newly formingmultiple sclerosis lesions, " Annals of Neurology, vol. 70, no. 1, pp. 22-29, 2011.
30. H. Lassmann, "Review: the architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis, " Neuropathology and Applied Neurobiology, vol. 37, no. 7, pp. 698-710, 2011.
31. J. W. Prineas and R. G. Wright, "Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis, " Laboratory Investigation, vol. 38, no. 4, pp. 409-421, 1978.
32. A. H. Cross, P. T. Manning, R. M. Keeling, R. E. Schmidt, and T. P. Misko, "Peroxynitrite formation within the central nervous system in active multiple sclerosis, " Journal of Neuroimmunology, vol. 88, no. 1-2, pp. 45-56, 1998.
33. E. Gray, T. L. Thomas, S. Betmouni, N. Scolding, and S. Love, "Elevated myeloperoxidase activity in white matter in multiple sclerosis, "Neuroscience Letters, vol. 444, no. 2, pp. 195-198, 2008.
34. T. Zeis, A. Probst, A. J. Steck, C. Stadelmann, W. Bruck, and N. Schaeren-Wiemers, "Molecular changes in white matter adjacent to an active demyelinating lesion in early multiple sclerosis: molecular changes in MS periplaque white matter, " Brain Pathology, vol. 19, no. 3, pp. 459-466, 2009.
35. M. T. Fischer, R. Sharma, J. L. Lim, et al., "NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury, " Brain, vol. 135, no. 3, pp. 886-899, 2012.
36. K. J. Smith, "Newly lesioned tissue in multiple sclerosis-a role for oxidative damage?" Brain, vol. 134, no. 7, pp. 1877-1881, 2011.
37. C. Schuh, I. Wimmer, S. Hametner, et al., "Oxidative tissue injury inmultiple sclerosis is only partly reflected in experimental disease models, " Acta Neuropathologica, vol. 128, no. 2, pp. 247-266, 2014.
38. B. M. Babior, J. D. Lambeth, and W. Nauseef, "The neutrophil NADPH oxidase, " Archives of Biochemistry and Biophysics, vol. 397, no. 2, pp. 342-344, 2002.
39. S. Li, A. C. Vana, R. Ribeiro, and Y. Zhang, "Distinct roleofnitric oxide and peroxynitrite in mediating oligodendrocyte toxicity in culture and in experimental autoimmune encephalomyelitis, " Neuroscience, vol. 184, pp. 107-119, 2011.
40. R. H. Hoek, S. R. Ruuls, C. A. Murphy, et al., "Down-regulation of the macrophage lineage through interaction with OX2 (CD200), " Science, vol. 290, no. 5497, pp. 1768-1771, 2000.
41. M. Gitik, S. Liraz-Zaltsman, P.-A. Oldenborg, F. Reichert, and S. Rotshenker, "Myelin down-regulates myelin phagocytosis by microglia and macrophages through interactions between CD47 on myelin and SIRPβ (signal regulatory protein-β) on phagocytes, " Journal of Neuroinflammation, vol. 8, article 24, 2011.
42. Y. Wang and H. Neumann, "Alleviation of neurotoxicity by microglial human Siglec-11, "TheJournal ofNeuroscience, vol. 30, no. 9, pp. 3482-3488, 2010.
43. R. M. Ransohoff and V. H. Perry, "Microglial physiology: unique stimuli, specialized responses, " Annual Review of Immunology, vol. 27, pp. 119-145, 2009.
44. V. H. Perry, J. A. R. Nicoll, and C. Holmes, "Microglia in neurodegenerative disease, " Nature Reviews Neurology, vol. 6, no. 4, pp. 193-201, 2010.
45. H. Konno, T. Yamamoto, H. Suzuki, et al., "Targeting of adoptively transferred experimental allergic encephalitis lesion at the sites of Wallerian degeneration, " Acta Neuropathologica, vol. 80, no. 5, pp. 521-526, 1990.
46. L. Haider, C. Simeonidou, G. Steinberger, et al., "Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron, " Journal of Neurology, Neurosurgery and Psychiatry, vol. 85, pp. 1386-1395, 2014.
47. B. Halliwell, "Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment, " Drugs & Aging, vol. 18, no. 9, pp. 685-716, 2001.
48. S. W. Hulet, E. J. Hess, W. Debinski, et al., "Characterization and distribution of ferritin binding sites in the adult mouse brain, " Journal of Neurochemistry, vol. 72, no. 2, pp. 868-874, 1999.
49. S. W. Hulet, S. Powers, and J. R. Connor, "Distribution of transferrin and ferritin binding in normal and multiple sclerotic human brains, " Journal of the Neurological Sciences, vol. 165, no. 1, pp. 48-55, 1999.
50. B. Hallgren and P. Sourand er, "The effect of age on the nonhaemin iron in the human brain, " Journal of Neurochemistry, vol. 3, no. 1, pp. 41-51, 1958.
51. K. I. Rathore, B. J. Kerr, A. Redensek, et al., "Ceruloplasmin protects injured spinal cord from iron-mediated oxidative damage, " The Journal of Neuroscience, vol. 28, no. 48, pp. 12736-12747, 2008.
52. S. Hametner, I. Wimmer, L. Haider, S. Pfeifenbring, W. Bruck, and H. Lassmann, "Iron and neurodegeneration in themultiple sclerosis brain, " Annals of Neurology, vol. 74, no. 6, pp. 848-861, 2013.
53. K. O. Lopes, D. L. Sparks, and W. J. Streit, "Microglial dystrophy in the aged and Alzheimers disease brain is associated with ferritin immunoreactivity, " Glia, vol. 56, no. 10, pp. 1048-1060, 2008.
54. W. Craelius, M. W. Migdal, C. P. Luessenhop, A. Sugar, and I. Mihalakis, "Iron deposits surrounding multiple sclerosis plaques, " Archives of Pathology & Laboratory Medicine, vol. 106, no. 8, pp. 397-399, 1982.
55. F. Bagnato, S. Hametner, B. Yao, et al., "Tracking iron inmultiple sclerosis: a combined imaging and histopathological study at 7 Tesla, " Brain, vol. 134, no. 12, pp. 3599-3612, 2011.
56. M. A. Friese, B. Schattling, and L. Fugger, "Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis, " Nature Reviews Neurology, vol. 10, no. 4, pp. 225-238, 2014.
57. H. Lassmann, J. Van Horssen, and D. Mahad, "Progressive multiple sclerosis: Pathology and pathogenesis, " Nature Reviews Neurology, vol. 8, no. 11, pp. 647-656, 2012.
58. H. Spatz, " Uber den eisennachweis im gehirn, besonders in zentren des extrapyramidal-motorischen systems. I. Teil, " Zeitschrift fur die Gesamte Neurologie und Psychiatrie, vol. 77, no. 1, pp. 261-390, 1922.
59. M. Vercellino, S. Masera, M. Lorenzatti, et al., "Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter, " Journal of Neuropathology and Experimental Neurology, vol. 68, no. 5, pp. 489-502, 2009.
60. A. Cifelli, M. Arridge, P. Jezzard, M. M. Esiri, J. Palace, and P. M. Matthews, "Thalamic neurodegeneration in multiple sclerosis, " Annals of Neurology, vol. 52, no. 5, pp. 650-653, 2002.
61. S. Murphy, "Production of nitric oxide by glial cells: Regulation and potential roles in the CNS, " Glia, vol. 29, no. 1, pp. 1-13, 2000.
62. M. T. Heneka and D. L. Feinstein, "Expression and function of inducible nitric oxide synthase in neurons, " Journal of Neuroimmunology, vol. 114, no. 1-2, pp. 8-18, 2001.
63. C. E. Cooper and G. C. Brown, "The interactions between nitric oxide and brain nerve terminals as studied by electron paramagnetic resonance, " Biochemical and Biophysical Research Communications, vol. 212, no. 2, pp. 404-412, 1995.
64. P. Mand er, V. Borutaite, S. Moncada, and G. C. Brown, "Nitric oxide from inflammatory-activated glia synergizes with hypoxia to induce neuronal death, " Journal of Neuroscience Research, vol. 79, no. 1-2, pp. 208-215, 2005.
65. A. Bal-Price and G. C. Brown, "Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity, " The Journal of Neuroscience, vol. 21, no. 17, pp. 6480-6491, 2001.
66. G. C. Brown, "Mechanisms of inflammatory neurodegeneration: INOS and NADPH oxidase, " Biochemical Society Transactions, vol. 35, no. 5, pp. 1119-1121, 2007.
67. S. Cho, E.-M. Park, P. Zhou, K. Frys, M. E. Ross, and C. Iadecola, "Obligatory role of inducible nitric oxide synthase in ischemic preconditioning, " Journal of Cerebral Blood Flow and Metabolism, vol. 25, no. 4, pp. 493-501, 2005.
68. V. Mehta, W. Pei, G. Yang, et al., "Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions, " PLoS ONE, vol. 8, no. 3, Article ID e57573, 2013.
69. K. H. Lee, S. J. Yun, K. N. Nam, Y. S. Gho, and E. H. Lee, "Activation of microglial cells by ceruloplasmin, " Brain Research, vol. 1171, no. 1, pp. 1-8, 2007.
70. I. Kawachi, "Deep greymatter involvement inmultiple sclerosis: key player or bystand er?" Journal of Neurology, Neurosurgery and Psychiatry, vol. 85, no. 12, p. 1293, 2014.
71. W. E. Klunk, J. C. Price, C. A. Mathis, et al., "Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees, " The Journal of Neuroscience, vol. 27, no. 23, pp. 6174-6184, 2007.
72. N. S. Ryan, S. Keihaninejad, T. J. Shakespeare, et al., "Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimers disease, " Brain, vol. 136, part 5, pp. 1399-1414, 2013.
73. S. Love, D. Louis, and D. W. Ellison, GreenfieldsNeuropathology, CRC Press, 2008.
74. S. DiMauro, E. A. Schon, V. Carelli, and M. Hirano, "The clinical maze of mitochondrial neurology, " Nature Reviews Neurology, vol. 9, no. 8, pp. 429-444, 2013.
75. N. K. Olsen, A. W. Hansen, S. Norby, A. L. Edal, J. R. Jorgensen, and T. Rosenberg, "Lebers hereditary optic neuropathy associated with a disorder indistinguishable from multiple sclerosis in a male harbouring the mitochondrial DNA 11778 mutation, " Acta Neurologica Scand inavica, vol. 91, no. 5, pp. 326-329, 1995.
76. M. E. Witte, D. J. Mahad, H. Lassmann, and J. van Horssen, "Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis, " Trends in Molecular Medicine, vol. 20, no. 3, pp. 179-187, 2014.
77. C. Lucchinetti, W. Bruck, J. Parisi, B. Scheithauer, M. Rodriguez, and H. Lassmann, "Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination, " Annals of Neurology, vol. 47, no. 6, pp. 707-717, 2000.
78. D. Mahad, I. Ziabreva, H. Lassmann, and D. Turnbull, "Mitochondrial defects in acute multiple sclerosis lesions, " Brain, vol. 131, no. 7, pp. 1722-1735, 2008.
79. R. Dutta, J. McDonough, X. Yin, et al., "Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients, " Annals of Neurology, vol. 59, no. 3, pp. 478-489, 2006.
80. G. R. Campbell, I. Ziabreva, A. K. Reeve, et al., "Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis, " Annals of Neurology, vol. 69, no. 3, pp. 481-492, 2011.
81. B. M. Babior, "NADPH oxidase, " Current Opinion in Immunology, vol. 16, no. 1, pp. 42-47, 2004.
82. A. Jekabsone, J. J. Neher, V. Borutaite, and G. C. Brown, "Nitric oxide from neuronal nitric oxide synthase sensitises neurons to hypoxia-induced death via competitive inhibition of cytochrome oxidase, " Journal of Neurochemistry, vol. 103, no. 1, pp. 346-356, 2007.
83. F. M. Yakes and B. VanHouten, "MitochondrialDNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress, " Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 2, pp. 514-519, 1997.
84. P. Mao and P. H. Reddy, "Is multiple sclerosis a mitochondrial disease?" Biochimicaet Biophysica Acta, vol. 1802, no. 1, pp. 66-79, 2010.
85. M. E. Witte, J. J. G. Geurts, H. E. de Vries, P. van der Valk, and J. vanHorssen, "Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration?" Mitochondrion, vol. 10, no. 5, pp. 411-418, 2010.
86. B. Halliwell and J. M. C. Gutteridge, "Oxygen toxicity, oxygen radicals, transition metals and disease, "TheBiochemical Journal, vol. 219, no. 1, pp. 1-14, 1984.
87. E. Cadenas, A. Boveris, C. I. Ragan, and A. O. M. Stoppani, "Production of superoxide radicals and hydrogen peroxide by NADH ubiquinone reductase and ubiquinol cytochrome c reductase from beef heart mitochondria, " Archives of Biochemistry and Biophysics, vol. 180, no. 2, pp. 248-257, 1977.
88. C. Nathan and A. Ding, "Snapshot: Reactive oxygen intermediates (ROI), " Cell, vol. 140, no. 6, pp. 951-951. e2, 2010.
89. T. Klimova and N. S. Chandel, "Mitochondrial complex III regulates hypoxic activation ofHIF, " Cell Death and Differentiation, vol. 15, no. 4, pp. 660-666, 2008.
90. M. P. Murphy, "How mitochondria produce reactive oxygen species, " The Biochemical Journal, vol. 417, no. 1, pp. 1-13, 2009.
91. D. C. Wallace, "Mitochondrial DNA mutations in disease and aging, " Environmental and MolecularMutagenesis, vol. 51, no. 5, pp. 440-450, 2010.
92. X. Qi, A. S. Lewin, L. Sun, W. W. Hauswirth, and J. Guy, "Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis, " The Journal of Biological Chemistry, vol. 281, no. 42, pp. 31950-31962, 2006.
93. N.-G. Larsson, "Somatic mitochondrial DNA mutations in mammalian aging, " Annual Review of Biochemistry, vol. 79, pp. 683-706, 2010.
94. H. Harris and D. C. Rubinsztein, "Control of autophagy as a therapy for neurodegenerative disease, " Nature Reviews Neurology, vol. 8, no. 2, pp. 108-117, 2012.
95. B. Ravikumar, S. Sarkar, J. E. Davies, et al., "Regulation of mammalian autophagy in physiology and pathophysiology, " Physiological Reviews, vol. 90, no. 4, pp. 1383-1435, 2010.
96. P. K. Stys, "General mechanisms of axonal damage and its prevention, " Journal of theNeurological Sciences, vol. 233, no. 1-2, pp. 3-13, 2005.
97. B. D. Trapp and P. K. Stys, "Virtual hypoxia and chronic necrosis of demyelinated axons inmultiple sclerosis, "TheLancet Neurology, vol. 8, no. 3, pp. 280-291, 2009.
98. B. Kornek, M. K. Storch, R. Weissert, et al., "Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions, " American Journal of Pathology, vol. 157, no. 1, pp. 267-276, 2000.
99. P. Werner, D. Pitt, and C. S. Raine, "Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage, " Annals of Neurology, vol. 50, no. 2, pp. 169-180, 2001.
100. S. Vergo, M. J. Craner, R. Etzensperger, et al., "Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model, " Brain, vol. 134, part 2, pp. 571-584, 2011.
101. S. G. Waxman, "Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status, " Nature Clinical Practice Neurology, vol. 4, no. 3, pp. 159-169, 2008.
102. J. Herschel, "A scaled ratio of body weight to brain weight of a comparative index for relative importance of brain size in mammals of widely varying body mass, " Psychological Reports, vol. 31, no. 1, pp. 84-86, 1972.
103. U. Graumann, R. Reynolds, A. J. Steck, and N. Schaeren-Wiemers, "Molecular changes in normal appearingwhitematter inmultiple sclerosis are characteristic of neuroprotectivemechanisms against hypoxic insult, " Brain Pathology, vol. 13, no. 4, pp. 554-573, 2003.
104. F. Aboul-Enein, H. Rauschka, B. Kornek, et al., "Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases, " Journal of Neuropathology and Experimental Neurology, vol. 62, no. 1, pp. 25-33, 2003.
105. T. Zeis, U. Graumann, R. Reynolds, and N. Schaeren-Wiemers, "Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection, " Brain, vol. 131, no. 1, pp. 288-303, 2008.
106. C. Stadelmann, S. Ludwin, T. Tabira, et al., "Tissue preconditioningmay explain concentric lesions in Balos type ofmultiple sclerosis, " Brain, vol. 128, no. 5, pp. 979-987, 2005.
107. A. N. Mhaille, S. McQuaid, A. Windebank, et al., "Increased expression of endoplasmic reticulum stress-related signaling pathway molecules in multiple sclerosis lesions, " Journal of Neuropathology and Experimental Neurology, vol. 67, no. 3, pp. 200-211, 2008.
108. J. M. McMahon, S. McQuaid, R. Reynolds, and U. F. Fitzgerald, "Increased expression of ER stress-and hypoxia-associated molecules in grey matter lesions in multiple sclerosis, " Multiple Sclerosis, vol. 18, no. 10, pp. 1437-1447, 2012.
109. W. T. Regenold, P. Phatak, M. J. Makley, R. D. Stone, and M. A. Kling, "Cerebrospinal fluid evidence of increased extramitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression, " Journal of the Neurological Sciences, vol. 275, no. 1-2, pp. 106-112, 2008.
110. C. A. Davie, C. P. Hawkins, G. J. Barker, et al., "Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions, " Brain, vol. 117, no. 1, pp. 49-58, 1994.
111. T. Haufschild, S. G. Shaw, J. Kesselring, and J. Flammer, "Increased endothelin-1 plasma levels in patients with multiple sclerosis, " Journal of Neuro-Ophthalmology, vol. 21, no. 1, pp. 37-38, 2001.
112. M. Pache, H. J. Kaiser, N. Akhalbedashvili, et al., "Extraocular blood flow and endothelin-1 plasma levels in patients with multiple sclerosis, " European Neurology, vol. 49, no. 3, pp. 164-168, 2003.
113. A. L. Davies, R. A. Desai, P. S. Bloomfield, et al., "Neurological deficits caused by tissue hypoxia in neuroinflammatory disease, " Annals of Neurology, vol. 74, no. 6, pp. 815-825, 2013.
114. B. Brownell and J. T. Hughes, "The distribution of plaques in the cerebrum in multiple sclerosis, " Journal of Neurology, Neurosurgery, and Psychiatry, vol. 25, pp. 315-320, 1962.
115. C. M. Holland, A. Charil, I. Csapo, et al., "The relationship between normal cerebral perfusion patterns and white matter lesion distribution in 1, 249 patients with multiple sclerosis, " Journal of Neuroimaging, vol. 22, no. 2, pp. 129-136, 2012.
116. M. A. Lee, S. Smith, J. Palace, et al., "Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?" Brain, vol. 122, part 7, pp. 1261-1270, 1999.
117. J. Lansley, D. Mataix-Cols, M. Grau, J. Radua, and J. Sastre-Garriga, "Localized grey matter atrophy in multiple sclerosis: a meta-analysis of voxel-based morphometry studies and associations with functional disability, " Neuroscience and Biobehavioral Reviews, vol. 37, no. 5, pp. 819-830, 2013.
118. N. Jafari and R. Q. Hintzen, "The association between cigarette smoking and multiple sclerosis, " Journal of the Neurological Sciences, vol. 311, no. 1-2, pp. 78-85, 2011.
119. M. A. Hernan, M. J. Olek, and A. Ascherio, "Cigarette smoking and incidence of multiple sclerosis, " American Journal of Epidemiology, vol. 154, no. 1, pp. 69-74, 2001.
120. M. Emre and C. de Decker, "Effects of cigarette smoking on motor functions in patients with multiple sclerosis, " Archives of Neurology, vol. 49, no. 12, pp. 1243-1247, 1992.
121. D. F. Church and W. A. Pryor, "Free-radical chemistry of cigarette smoke and its toxicological implications, " Environmental Health Perspectives, vol. 64, pp. 111-126, 1985.
122. W. C. Butts, M. Kuehneman, and G. M. Widdowson, "Automated method for determining serum thiocyanate, to distinguish smokers from nonsmokers, " Clinical Chemistry, vol. 20, no. 10, pp. 1344-1348, 1974.
123. J. Zambonin, S. Engeham, G. R. Campbell, et al., "Identification and investigation of mitochondria lacking cytochrome c oxidase activity in axons, " Journal ofNeuroscienceMethods, vol. 192, no. 1, pp. 115-120, 2010.
124. I. Tellez, D. Johnson, R. L. Nagel, and A. Cerami, "Neurotoxicity of sodium cyanate. New pathological and ultrastructural observations in Macaca nemestrina, " Acta Neuropathologica, vol. 47, no. 1, pp. 75-79, 1979.
125. D. J. Philbrick, J. B. Hopkins, D. C. Hill, J. C. Alexander, and R. G. Thomson, "Effects of prolonged cyanide and thiocyanate feeding in rats, " Journal of Toxicology and EnvironmentalHealth, vol. 5, no. 4, pp. 579-592, 1979.
126. A. Ohnishi, C. M. Peterson, and P. J. Dyck, "Axonaldegeneration in sodium cyanate induced neuropathy, " Archives of Neurology, vol. 32, no. 8, pp. 530-534, 1975.
127. H. D. Jonez, "Multiple sclerosis; treatment with histamine and d-tubocurarine, " Annals of allergy, vol. 6, no. 5, pp. 550-563, 1948.
128. R. M. Brickner, "Pharmacological reduction of abnormality in multiple sclerosis within minutes: a statistical study, " The Journal of Nervous and Mental Disease, vol. 127, no. 4, pp. 308-322, 1958.
129. B. T. Horton, "The clinical use of histamine, " Postgraduate Medicine, vol. 9, no. 1, pp. 1-10, 1951.
130. B. H. Fischer, M. Marks, and T. Reich, "Hyperbaric-oxygen treatment of multiple sclerosis. A rand omized, placebocontrolled, double-blind study, " The New England Journal of Medicine, vol. 308, no. 4, pp. 181-186, 1983.
131. M. Bennett and R. Heard, "Hyperbaric oxygen therapy for multiple sclerosis, " CNSNeuroscience&Therapeutics, vol. 16, no. 2, pp. 115-124, 2010.
132. J. M. McCord, "Oxygen-derived free radicals in postischemic tissue injury, "The New England Journal ofMedicine, vol. 312, no. 3, pp. 159-163, 1985.
133. L. di Nuzzo, R. Orland o, C. Nasca, and F. Nicoletti, "Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis, "DrugDesign, Development and Therapy, vol. 8, pp. 555-568, 2014.
134. E. Hondares, O. Mora, P. Yubero, et al., "Thiazolidinediones and rexinoids induce peroxisome proliferator-activated receptorcoactivator (PGC)-1alpha gene transcription: an autoregulatory loop controls PGC-1alpha expression in adipocytes via peroxisome proliferator-activated receptor-gamma coactivation, " Endocrinology, vol. 147, no. 6, pp. 2829-2838, 2006.
135. K. S. Shindler, E. Ventura, M. Dutt, P. Elliott, D. C. Fitzgerald, and A. Rostami, "Oral resveratrol reduces neuronal damage in a model of multiple sclerosis, " Journal of Neuro-Ophthalmology, vol. 30, no. 4, pp. 328-339, 2010.
136. M. E. Witte, P. G. Nijland, J. A. R. Drexhage, et al., "Reduced expression of PGC-1β partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex, " Acta Neuropathologica, vol. 125, no. 2, pp. 231-243, 2013.
137. M. Forte, B. G. Gold, G. Marracci, et al., "Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 18, pp. 7558-7563, 2007.
138. K. Su, D. Bourdette, and M. Forte, "Genetic inactivation of mitochondria-targeted redox enzyme p66shcA preserves neuronal viability and mitochondrial integrity in response to oxidative challenges, " Frontiers in Physiology, vol. 3, article 285, 2012.
139. X. Qi, A. S. Lewin, L. Sun, W. W. Hauswirth, and J. Guy, "Suppression of mitochondrial oxidative stress provides long-term neuroprotection in experimental optic neuritis, " Investigative Ophthalmology & Visual Science, vol. 48, no. 2, pp. 681-691, 2007.
140. P. Mao, M. Manczak, U. P. Shirendeb, and P. H. Reddy, "MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mousemodel ofmultiple sclerosis, " Biochimicaet Biophysica Acta-Molecular Basis of Disease, vol. 1832, no. 12, pp. 2322-2331, 2013.
141. S. Sawcer, G. Hellenthal, M. Pirinen, et al., "Genetic risk and a primary role for cell-mediatedimmunemechanisms inmultiple sclerosis, " Nature, vol. 476, no. 7359, pp. 214-219, 2011.
142. M. Prinz, H. Schmidt, A. Mildner, et al., "Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system, " Immunity, vol. 28, no. 5, pp. 675-686, 2008.
143. M. Comabella, J. D. Lunemann, J. Rio, et al., "A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis, " Brain, vol. 132, no. 12, pp. 3353-3365, 2009.
144. P. H. Lalive, O. Neuhaus, M. Benkhoucha, et al., "Glatiramer acetate in the treatment ofmultiple sclerosis: emerging concepts regarding its mechanism of action, " CNS Drugs, vol. 25, no. 5, pp. 401-414, 2011.
145. H.-P. Hartung, R. Gonsette, N. Konig, et al., "Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, doubleblind, rand omised, multicentre trial, " The Lancet, vol. 360, no. 9350, pp. 2018-2025, 2002.
146. R. A. Linker, D.-H. Lee, S. Ryan, et al., "Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway, " Brain, vol. 134, no. 3, pp. 678-692, 2011.
147. V. E. Miron, S. K. Ludwin, P. J. Darlington, et al., "Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices, " The American Journal of Pathology, vol. 176, no. 6, pp. 2682-2694, 2010.
148. L. Kappos, H. Hartung, M. S. Freedman, et al., "Atacicept in multiple sclerosis (ATAMS): a rand omised, placebo-controlled, double-blind, phase 2 trial, " The Lancet Neurology, vol. 13, no. 4, pp. 353-363, 2014.
149. A. P. Gregory, C. A. Dendrou, K. E. Attfield, et al., "TNFreceptor genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis, " Nature, vol. 488, no. 7412, pp. 508-511, 2012.
150. B. M. Segal, C. S. Constantinescu, A. Raychaudhuri, L. Kim, R. Fidelus-Gort, and L. H. Kasper, "Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, rand omised, dose-ranging study, " The Lancet Neurology, vol. 7, no. 9, pp. 796-804, 2008.
151. A. Haghikia, R. Hohlfeld, R. Gold, and L. Fugger, "Therapies for multiple sclerosis: translational achievements and outstand ing needs, " Trends inMolecularMedicine, vol. 19, no. 5, pp. 309-319, 2013.
152. R. Gold, L. Kappos, D. L. Arnold, et al., "Placebo-controlled phase 3 study of oral BG-12 for relapsingmultiple sclerosis, " The New England Journal ofMedicine, vol. 367, no. 12, pp. 1098-1107, 2012.